Crinetics Pharmaceuticals, Inc. 4

Director Matthew K. Fust had all of his Crinetics Pharmaceuticals common stock, RSUs, and in-the-money stock options canceled and cashed out at the $85.00-per-share merger price in the September 1, 2026 acquisition by Vertex Pharmaceuticals.

On September 1, 2026, in conjunction with the acquisition of Crinetics Pharmaceuticals, Inc. by Vertex Pharmaceuticals, all of Matthew K. Fust’s equity in Crinetics was canceled and cashed out at the $85.00 per share merger price. This included 22,836 shares of common stock (with 5,925 shares shown as a separate line of common stock/RSUs) converted into cash at $85 per share, as well as multiple tranches of vested stock options with various exercise prices that were canceled in exchange for cash equal to the $85.00 merger consideration minus each option’s strike price. Specifically, options for 2,092 shares at a $1.91 strike, 17,500 shares at $20.32, 12,500 shares at $44.71, 10,350 shares at $32.33, and 9,730 shares at $35.87 were all cashed out based on their intrinsic value (with option values per share of $83.09, $64.68, $40.29, $52.67, and $49.13, respectively), while any options with exercise prices at or above $85.00 were canceled for no consideration. Following the closing of the merger, Fust no longer holds Crinetics equity as the company became a wholly owned subsidiary of Vertex.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-059902

Alert Tier

6